Earn ACPE credit without BCPP recertification credit

ACPE #0284-0000-24-002-H01-P (Knowledge)
Author: Robin Hieber, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for anxiety and anxiety-related disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for anxiety and anxiety-related disorders.
2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of anxiety and anxiety-related disorders.
3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of anxiety and anxiety-related disorders. 
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in anxiety and anxiety-related disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for anxiety and anxiety-related disorders. 
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of anxiety and anxiety-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with anxiety and anxiety-related disorders.

ACPE #0284-0000-24-004-H01-P (Knowledge)
Author: Jeremy Daniel, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for bipolar disorder, including the list of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for bipolar disorder.
2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of bipolar disorder.
3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of bipolar disorder.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in bipolar disorder.
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for bipolar disorder.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of bipolar disorder in special populations (i.e., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with bipolar disorder.

ACPE #0284-0000-24-001-H04-P (Knowledge)
Author: Carol Ott, PharmD, BCPP, Chris Paxos, PharmD, BCPP, BCPS, BCGP
Learning Objectives
At the end of this program, the participant should be able to:

1. Identify social and cultural norms that can impact therapeutic outcomes.
2. List the essential components of the psychiatric interview.
3. Explain the role of the psychiatric interview in the collection of health and medication history.
4. Explain the rationale for collection of collateral information by the treatment team.
5. Describe the features of care coordination and transitional care models of care and the role of the pharmacist in these processes.
6. Identify principles and methods for educating health care professionals.
7. Identify principles and methods for educating patients and the public.
8. Explain procedures for assessing the effectiveness of education of patients and the public.
9. Identify principles of health literacy.
10. Outline principles, processes and measures for measuring the effectiveness of psychiatric pharmacy services.
11. Outline known disparities in psychotropic medication use on the basis of ethnicity, gender/gender identity, and geographic location.
12. Identify pharmacist practice models that address known gaps in care of psychiatric disorders.
13. Identify methods to provide and assess medication education to patients, families, and caregivers in individual and group sessions, and improve adherence.

ACPE #0284-0000-24-007-H01-P (Knowledge)
Author: Sandra Mullen, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, and conduct disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for these disorders.
2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders. 
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders.
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders. 
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
   1. Down Syndrom
   2. Prader-Willi Syndrome
   3. Fragile X Syndrome
   4. Klinefelter’s Syndrome
   5. Rett's Syndrome
10. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.

ACPE #0284-0000-24-009-H01-P (Knowledge)
Author: Lindsey Miller, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for personality disorders and eating disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for personality disorders and eating disorders.
2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of personality disorders and eating disorders.
3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of personality disorders and eating disorders. 
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in personality disorders and eating disorders.
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for personality disorders and eating disorders. 
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of personality disorders and eating disorders in special populations (e.g., pregnancy/lactation, children, and elderly patients).
9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with personality disorders and eating disorders.

ACPE #0284-0000-24-011-H01-P (Knowledge)
Author: Charles Caley, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for schizophrenia spectrum, other psychotic disorders, and movement disorders, including the lists of medications, substances, and diseases that can cause or worsen symptoms for these disorders.
2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of schizophrenia spectrum, other psychotic disorders, and movement disorders.
3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of schizophrenia spectrum, other psychotic disorders, and movement disorders.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in schizophrenia spectrum, other psychotic disorders, and movement disorders.
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and practice implications for schizophrenia spectrum, other psychotic disorders, and movement disorders. 
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of schizophrenia spectrum, other psychotic disorders, and movement disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with schizophrenia spectrum, other psychotic disorders, and movement disorders.
10. Describe provider behaviors and responses, environmental responses, and de-escalation techniques useful for calming agitated patients.

ACPE #0284-0000-24-013-H01-P (Knowledge)
Author: Erika Titus-Lay, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for substance-related disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for substance-related disorders.
2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of substance-related disorders.
3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of substance-related disorders. 
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for substances used in substance-related disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for substance-related disorders. 
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of substance-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with substance-related disorders.